The transforming growth factor-b (TGF-b) binds the type II TGF-b growth factor receptor (RII) to inhibit the growth of most epithelial tissues. Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the RII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-b resistance. To further investigate the type, frequency and tissue distribution of RII mutations, we selected 24 human cancer cell lines from various tissues which were previously reported to be resistant to the inhibitory eects of TGF-b. We developed protocols for non-isotopic SSCP analysis of PCR products from genomic DNA samples, and we tested them for microsatellite instability. PCR ± SSCP analysis followed by DNA sequencing identi®ed deletion mutations in the exon 3 poly-adenine tract in three colon tumor cell lines: LS174T and SW48 had a single base deletion and LS411 had a two base deletion. Among the 24 previously unreported cell lines, only these three demonstrated microsatellite instability. These and other recent data indicate that RII mutations are essentially con®ned to colon and gastric cancers with microsatellite instability. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.
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Keywords: single-strand conformation polymorphism analysis; somatic mutation; polymerase chain reaction; genomic DNA; microsatellite instability Transforming growth factor-b (TGF-b) restrains the proliferation of normal epithelial cells, and diminished responsiveness to TGF-b is a common feature of epithelial cancers (reviewed in Yingling et al., 1995; Lin and Moustakas, 1994; Attisano et al., 1994) . TGF-b binds the TGF-b type II receptor (RII), and the duplex recruits the type I receptor to form an active complex . RII is a constitutively active serine/threonine kinase which phosphorylates the type I receptor, also a serine/threonine kinase, which in turn phosphorylates one or more substrates to initiate the signal cascade. Candidate substrates include a WDdomain protein associated with and phosphorylated by RII (Chen et al., 1995) and several novel human genes related to a Drosophila gene called mad which are either mutated or deleted in colon cancer (Riggins et al., 1996) . Experiments demonstrating mutational inactivation of (Markowitz et al., 1995a; Lu et al., 1995) and growth suppression by the RII (Sun et al., 1994; Wang et al., 1995) have raised the hypothesis that RII is a tumor suppressor gene.
RII mutations have been predominantly frameshifts in nucleotide repeats in colon and gastric cancers with microsatellite instability (MI, see Parsons et al., 1995; Markowitz et al., 1995; Lu et al., 1995; Wang et al., 1995; Myero et al., 1995) . These mutations are characteristic of the mismatch repair de®cit found in hereditary non-polyposis colon cancers which have MI and frequent mutations in the hMSH2 and hMLH1 genes (Liu et al., 1996) . There have been few studies of tumors other than colon, gastric, and endometrial, so we decided to survey human cell lines known to be resistant to TGF-b which represent several dierent human tissues. We selected 24 cell lines established from human cancers of the lung, colon, breast, leukemia, head and neck, cervix, pancreas, prostate and retina; all have been shown to be resistant to growth inhibition by TGF-b (Fynan and Reiss, 1993) . We tested three mutational hotspots in exons 3, 5 and 7 of the RII gene because four dierent groups analysed complete coding sequences of RII in colon Takenoshita et al., 1997a) and squamous tumors (Garrigue-Antar et al., 1995) and found mostly deletions in the poly-adenine tract (exon 3), occasional missense mutations in exons 5 or 7, and wild type sequences in exons 1, 2, 4 and 6. To analyse genomic DNA samples, we used a novel, rapid sequencing protocol to determine the genomic structure of the RII, designed intron primers for PCR ± SSCP analysis (Takenoshita et al., 1996) and developed a non-isotopic PCR ± SSCP assay. Mobility shifts were obtained for exon 3 (Figure  1 ), and exons 5 and 7 (Figure 2 ) using the following mutant controls: RKO has a two-base pair deletion in a poly-adenine tract at codons 126 ± 129 (exon 3, see Markowtiz et al., 1995a) , DLD-1 has a missense mutation at codon 452 (exon 5, see Parsons et al., 1995) , and A253 has a missense mutation at codon 537 (exon 7, see Garrigue-Antar et al., 1995) . Compared to the wild type and mutant controls, the LS174T, SW48 and LS411 colon cancer cell lines had mobility shifts in exon 3 by SSCP analysis (Figure 1 ). DNA sequencing identi®ed deletions in the exon 3 poly-adenine tract: LS174T and SW48 have a single base deletion and LS411 has a two base deletion (Figure 3 ). These frameshifts lead to premature terminations and predicted proteins of 161 amino acids and 129 amino acids, respectively; both are substantially smaller than the normal protein of 565 amino acids and would be expected to interrupt the serine/threonine kinase function.
To determine whether these mutations are associated with MI, we tested the BAT-26 microsatellite marker located within intron 5 of the hMSH2 gene at chromosome 2p22.23. In the absence of non-neoplastic tissues for the cancer cell lines, MI was analysed by amplifying the BAT-26 microsatellite, which is less polymorphic than other commonly tested microsatellites (M Nagashima, unpublished observation), and comparing the mobility shifts to ®ve DNA samples from non-neoplastic human tissues. Five cell lines, Figure 1 Non-isotopic SSCP analysis of exon 3 of the TGF-b type II receptor. Method. Puri®ed PCR products were denatured by mixing with an equal volume of formamide (85% formamide, 10 mM EDTA, 0.25% bromophenol blue and xylene cyanol) and incubating at 95 ± 1008C for 5 min, with subsequent rapid cooling to 08C before applying 1 ml of each sample onto the gel. SSCP analysis was performed using the PhastSystem TM (Pharmacia Biotechnology, Uppsala, Sweden), a semiautomated electrophoresis and staining system. Electrophoresis was done using precast homogeneous 20% polyacrylamide gels with Native Buer Strips TM (Pharmacia Biotechnology, Uppsala, Sweden). Running conditions were 48C/750 volt-hours (vh) and 158C/700 vh for exons 3 and 7, and 108C/750 vh and 158C/700 vh for exon 5. Bands were visualized by silver staining using the manufacturer's reagents and protocols. Mutant controls were used to develop the SSCP conditions; these were PCR products produced from genomic DNA of human cancer cell lines with known mutations: RKO (colon) has a two-base deletion in the poly-A 10 tract at nucleotides 709 to 718 , DLD-1 (colon) has a missense mutation at codon 452 in exon 5 , and A253 (oral squamous cell carcinoma) has a missense mutation at codon 537 in exon 7 (Garrigue-Antar et al., 1995) . Figure 4 ). These mobility shifts were interpreted as MI, and this conclusion was supported by previous reports that both HCT116 and RKO have MI and deletions in the RII poly-adenine tract Markowitz et al., 1995) . It is notable that the A253 oral cancer cell line lacks MI at BAT-26, though it carries a missense mutation at codon 537. It is also interesting that several tumor cell lines (i.e., MCF-7, MDA-MB231, C4-1, CASKI, HUT292, and SCC4) had both the normal mobility band plus minor, smaller bands which may represent subpopulations with MI. Mutations in the RII gene conferring resistance to TGF-b occur in most colon Markowitz et al., 1995; Lu et al., 1995; ,
A (10) A (9) A (9) A(8) Figure 3 DNA sequence analysis of exon 3 of the TGF-b RII. PCR products from mutant controls and samples with SSCP mobility shifts were directly sequenced using the Sequenase PCR product sequencing kit (Amersham Life Technology, Arlington Heights, IL). Four ml of PCR product were treated with exonuclease and Shrimp Alkaline Phosphatase and sequenced using PCR primers and conditions speci®ed by the manufacturer. Three samples which showed a mobility shift by SSCP analysis were subjected to sequence analysis which demonstrated deletions of one or two adenines in SW48, LS174, and LS411 (the non-coding, transcribed strand is shown so there are 10, 9 or 8 consecutive thymidines) 1 2 3 4 5 MCF-7 MDA-M468-S4 MDA-MB231   T47D  C4-1  CASKI  SIHA  HT29  SW480  SW620  SW837  KG-1  CALU1  HUT292  FaDu  SCC13  SCC25  SCC4  MIA-PACA   WERI  Y79  A253  SW48  LS-174-T  LS411  HCT116 RKO Non-tumor Control Figure 4 Analysis of microsatellite instability in 27 human cancer cell lines and ®ve non-neoplastic DNA samples. Methods. The BAT-26 microsatellite marker, located within intron 5 of hMSH2 at chromosome 2p22.23 has an approximately 26 bp poly-adenine mononucleotide repeat sequence (Liu et al., 1996) . The PCR primers were the following: forward, 5'-TGACTACTTTTGACTT-CAGCC-3', and reverse, 5'-AACCATTCAACATTTTTAACCC-3'. Approximately 50 ng of genomic DNA template were suspended in a total volume of 10 ml PCR reaction mixture containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1 mM MgCL 2 , 300 nM each primer, 100 mM of each dNTP, 0.25 ml of alpha-32 P-labelled dCTP (3000 Ci/mmol; 10 mCi/ml), and 1 unit of Taq DNA polymerase. PCR was performed by 30 cycles of ampli®cation composed of 40 s at 948C for denaturation, 30 s at 508C for annealing and 90 s at 728C for extension. The PCR products were diluted 10-fold with denaturing solution containing 96% formamide, 20 mM EDTA, 0.05% bromophebnol blue, and 0.05% xylene cyanol. After the samples were heated at 808C for 2 min, 1.5 ml of diluted sample were electrophoresed on a 6% denaturing polyacrylamide gel containing 7M urea at room temperature; the gel was dried and autoradiographed (XAR-5 ®lm, Eastman Kodak Co., Rochester, NY). In the absence of normal tissue for each cell line, the mobilities were compared to ®ve samples from non-neoplastic tissues. We considered a sample to have MI when the mobility of the microsatellite PCR product was grossly altered compared to the ®ve non-tumor control samples. Samples. Five nonneoplastic tissues have a uniform migration pattern, and ®ve tumor samples (SW48, LS-174T, LS411, HCT116, RKO) have gross mobility shifts indicating microsatellite instability. Several samples had both the normal mobility band plus additional, minor, smaller bands which may represent subpopulations with microsatellite instability; these included MCF-7, MDA-MB231, C4-1, CASKI, HUT292 and SCC4 TGF-b type II receptor mutations in sporadic cancer cell lines F Vincent et al 1995) and gastric cancers with MI. The mutations cluster predominantly in a polyadenine tract in exon 3, occasionally in a GT 3 repeat in exon 7 (Park et al., 1994; Parsons et al., 1995; Myero et al., 1995) , and rare missense mutations occur in domains IX and XI of the kinase region in exons 5 and 7 Garrigue-Antar et al., 1995) . We investigated the distribution and frequency of these mutations in other epithelial tissues that commonly produce cancers by testing 24 cell lines known to be resistant to TGF-b. We found poly-adenine tract mutations in three colon cancers with MI; four other colon cancers and all other cell lines had neither RII mutations nor MI (see Table 1 ). This is consistent with our own series of sporadic tumors of the colon (Takenoshita et al., 1997a) , lung (Takenoshita et al., 1997b) , pancreas, breast and liver (Vincent et al., 1996) , and recent literature reports Wang et al., 1995; Garrigue-Antar et al., 1995; Lu et al., 1995; Parsons et al., 1995; Myero et al., 1995) .
Several new members of the TGF-b signal transduction pathway have been described (Riggins et al., 1996) , and the restriction of RII mutations to colon tumors suggests these new components as targets for mutational inactivation in other tissues. There is already some evidence for this since the MDA-MB468 breast cancer cell line, which lacks MI and RII mutation, has homozygous deletion of the DPC4 gene which was recently linked to the TGF-b pathway . SW480, which lacks MI and RII mutation, may be another example, since microcellmediated transfer of chromosome 18 restores responsiveness to TGF-b and suppresses its tumorigenicity (Goyette et al., 1992) ; this is consistent with restoration of DPC4 or another mad-related gene (Eppert et al., 1996) , both located on chromosome 18q. Three other cell lines are monosomic for madgenes on chromosomes 5 (JV5-1), 15 (JV15-1, JV15-2) and 18 (DPC4 and JV18-1); KG-1 has monosomy 5, MDA-MB231 lacks both copies of chromosome 15, and SW837 is monosomic for chromosomes 15 and 18 MI, microsatellite instability; adenoca, adenocarcinoma; SCC, squamous cell carcinoma; poly-A, poly-adenine; del A, delete one A; del AA, delete two As; POS, positive; neg, negative; na, not analysed. a TGF-b inhibition according to (Fynan and Reiss, 1993) . b M Steed, personal communication. Sample Selection. Twenty-four human cancer cell lines from breast, lung, leukemia, head and neck, retina, cervix, colon and pancreas were chosen for complete or substantial resistance (Fynan and Reiss., 1993) to growth inhibition by TGF-b. Genomic DNA was isolated from cell cultures by proteinase K treatment and phenol-chloroform extraction using standard methods. PCR Primers and Ampli®cation Conditions. Primers sets were designed based on the RII genomic sequence (Genbank# U52240-U52245) as previously reported (Takenoshita et al., 1997a) . Exon 3 (codon 88 ± 152) contains the poly-adenine repeat, and intron primers were designed: forward, 5'-TGCAATGAATCTCTTCACTC-3' and reverse, 5'-CCCACACCCTTAAGAGAAGA-3'. Exon 5 (codons 419 ± 466) contains kinase domain IX, and intron primers were designed: forward, 5'-GGCAGCTGGAATTAAATGATGGGC-3' and reverse, 5'-TGCTCGAAGCAACACATG-3'. Exon 7 (codons 509 ± 575) contains part of the kinase domain XI which includes two GT 3 repeats, and primers were designed: forward, 5'-CCAACTCATGGTGTCCCTTTG-3' (intron) and reverse, 5'-TCTTTGGACATGCCCAGCCTG-3' (exon, codons 562 to 569). For exons 3, 5 and 7, 50 to 100 nanograms of genomic DNA were used as template, and PCR ampli®cation was performed with AmpliTaq DNA polymerase (PerkinElmer, Inc., Foster City, CA) in a DNA thermal cycler (Perkin-Elmer, Inc., Foster City, CA) using 35 cycles: 1 min at 948C, 50 at 558C and 30 at 728C. The AmpliTaq buer included ®nal concentrations of 60 mM Tris HCl, pH 9.0, 2 mM MgCl 2 , 15 mM (NH 4 ) 2 SO 4 , 2.5 mM for each dNTP and each primer at 200 picomolar concentration (i.e., 20 picomoles per 100 ml reaction). Ampli®cation products for exons 3,5 and 7 were 240, 255 and 250 bp, respectively (American Type Culture Collection, 1992) . We are currently analysing these and other cell lines for mutations in the mad-genes.
Several other mechanisms causing TGF-b resistance in vitro have been described, such as introducing the SV40 large T antigen, human papilloma virus (HPV) type 16 E6 and E7 oncoproteins (Pietenpol et al., 1990) or adenovirus E1A oncoprotein (Missero et al., 1991; Mal et al., 1996) . In our series, all cervical cancer cell lines contained carcinogenic strains of HPV; C4-1 has type 18, and CASKI and SIHA have type 16). The C4-1 and CASKI cell lines express normal levels of RII mRNA (Garrigue-Antar et al., 1995) , and the E6 and E7 oncoproteins may obviate mutational inactivation of RII. Some mutant forms of the p53 tumor suppressor gene block TGF-b signal transduction , and this may explain the resistance of our breast cancer cell lines which have p53 missense mutations (except MCF7, see Hollstein et al., 1996) as well as detectable levels of RII mRNA and protein (except T47D, see Kalkhoven et al., 1995) . Similarly, the four oral cancer cell lines have p53 mutations (three missense and one frameshift, see Hollstein et al., 1996) and no evidence of RII mutations.
Additional mechanisms of TGF-b resistance include expression of a dominant-negative form of RII (Chen et al., 1993) , and overexpression of CDK4 (Ewen et al., 1993) , E2F1 (Schwarz et al., 1995) , or c-myc oncoprotein (Alexandrow et al., 1995) . The WERI and Y79 retinoblastoma cell lines have pRB mutations which abrogate pRB mediated c-myc regulation; this interrupts the c-myc pathway mediating growth inhibition in response to TGF-b (Pietenpol et al., 1990 (Pietenpol et al., , 1991 . Recent reports link ras proteins to the TGF-b pathway (Wang et al., 1996; Yan et al., 1994; Howe et al., 1993; Zabrenetzky et al., 1994) , and the MIA-PACA-2 (undetectable RII mRNA, see Freeman et al., 1995) pancreatic cell line and the CALU-1 (normal RII mRNA and protein, see Garrigue-Antar et al., 1995) lung cancer line have both K-ras and p53 mutations. Over-expression of cyclin D1 has been shown to down-regulate RII expression (Okamoto et al., 1994) , and this might explain the undetectable levels of both RII and mRNA and protein (Winesett et al., 1996) in two colon cancer cell lines, HT29 and SW620, which lack MI and RII mutation.
Tissue-speci®c alterations have been noted for several tumor suppressor genes, including DPC4, APC and p16; for example, DPC4 inactivation occurs in 48% of pancreatic tumors but rarely in other common carcinomas . Our studies suggest that RII may be added to this list, and the several mechanisms producing TGF-b resistance plus the susceptibility of RII to frameshift deletion may explain the restriction of RII mutations to colon cancers with MI. Recent reports describe several new members of a TGF-b signal transduction pathway (Riggins et al., 1996; Massague, 1996) , and analysis of these genes may show additional mechanisms by which tumors evade control by TGF-b.
Abbreviations SSCP, single-strand conformation polymorphism analysis; TGF-b, transforming growth factor-b; RII, TGF-b type II receptor; bp, base pair; nt, nucleotide; DS, double stranded DNA; sec, second; C, centigrade; MI, microsatellite instability; HPV, human papillomavirus; APC, adenomatous polyposis coli; DPC4, deleted in pancreatic cancer #4.
